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Introduction
The genomic era was ushered in when the human genome
project began cloning each of our >30,000 genes. Since
this endeavor is essentially complete we are, in a sense,
entering the post-genomic era. The explosion in biological
information issuing from the human genome project
promises major improvements in health care and a revo-
lution in the treatment of numerous diseases, including
cancer. At the same time, while this may be the crowning
achievement of the biotechnological revolution, it rep-
resents only a part of the progress that has been made. In
cancer diagnosis and therapy, novel biology-based para-
digms are being generated that threaten to profoundly
alter the practice of cancer therapy.
A keystone concept (Figure 1) is that we will be able
to use genome-based biotechnology approaches to accu-
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The cloning of the human genome has generated a tremendous resource of information that will improve treatment of
cancer, and other diseases. Allied to these discoveries are powerful new investigative tools that have been, and are being,
developed. These are being used to give a comprehensive biological profile of individuals and their cancer that will allow better
classification, as well as identification of pathways that might be targeted with therapeutic benefit. The hope is that these
approaches will allow intervention that is tailored to the needs of the individual patient and that the targeted cancer therapies
will be associated with less toxicity than those currently used. This raises questions as to how best to use the new biotechnologies
to predict responses to conventional therapies and indeed will conventional therapies, like radiation therapy, have a role in
cancer treatment as specific biologically targeted drugs become commonplace. Here, it is argued that even the molecular staging
of cancer that is currently being performed, if exploited correctly, will greatly aid patient selection for radiation therapy and that
this should be the starting point for further studies aimed at developing predictive profiles for improving treatment outcome.
It is also argued that because the biological anti-cancer agents target molecular pathways that overlap with those responsible
for radiosensitivity, and because on their own they have little cytotoxic power, radiation therapists should incorporate
biological agents into combined modality regimens and that this is likely to be a standard form of treatment in the next decade.
Przysz∏oÊç radioterapii w erze genomu
Sklonowanie ludzkiego genomu dostarczy∏o ogromnej iloÊci informacji, które z pewnoÊcià przyczynià si´ do post´pu w dzie-
dzinie leczenia wielu schorzeƒ, nie tylko o charakterze nowotworowym. Rozwój ten wspomagany jest równie˝ przez pot´˝ne na-
rz´dzia badawcze, które znalaz∏y si´ ostatnio w naszym zasi´gu. Dzi´ki zdobytej wiedzy i mo˝liwoÊciom mo˝emy w chwili obec-
nej analizowaç profile biologiczne nowotworów i ich „˝ywicieli”, przyczyniajàc si´ do zwi´kszenia skutecznoÊci leczenia
oraz do zmniejszenia jego toksycznoÊci. Niestety, jak przy ka˝dej nowej metodzie, tak i w tym przypadku rodzà si´ pytania – jak
zastosowaç najnowsze osiàgni´cia biotechnologii dla przewidzenia odpowiedzi na leczenie konwencjonalne i na metody
bardziej nowoczesne. Istotne jest równie˝ przewidzenie miejsca radioterapii w leczeniu chorych w chwili, gdy wysoce specyficz-
ne preparaty celowane biologicznie stanà si´ elementem rutynowego post´powania. Wydaje si´ byç celowym zaznaczenie, ˝e
"staging" molekularny guza nowotworowego mo˝e znacznie wspomóc wyselekcjonowanie grupy chorych, którzy najbardziej sko-
rzystajà na leczeniu radioterapià, i ˝e w∏aÊnie taki sposób rozumowania powinien le˝eç u podstaw prac majàcych na celu dal-
szy rozwój terapii w onkologii. Co wi´cej, postuluje si´, ˝e drogi metaboliczne, okreÊlane dzi´ki wnikliwej analizie guzów, mo-
gà, do pewnego stopnia, pokrywaç si´ z mechanizmami promieniowra˝liwoÊci, a zatem lekarze radioterapeuci mogà si´gaç po
preparaty biologicznie celowane, aby poprawiç skutecznoÊç swego post´powania. Nale˝y sàdziç, ˝e tak zmodyfikowane lecze-
nie stanie si´ standardem w czasie nadchodzàcego dziesi´ciolecia.
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rately define the molecular profile of the patient and of
their cancer and identify pathways that can be specifical-
ly targeted by “smart” drugs. In this way therapeutic inter-
vention will be tailored to the individual patient to maxi-
mize therapeutic benefit. It is always difficult to predict
the future, and this presentation should be considered
as containing personal and at times deliberately provoca-
tive views, but it seems that this is an appropriate time to
consider the place of radiation therapy in the proposed
new world of cancer therapy.
The current state of biotechnology
The human genome project may be rewriting the lan-
guage of biology, but it is the high throughput biotech-
nologies that are generating the individual words and it is
the field of bioinformatics that is charged with generating
the syntax that allows this language to be placed into
a readable, or at least semi-readable, form. They allow
a holistic approach to scientific investigations that com-
plements the more traditional reductionist mechanistic
approach.
At the genetic level, variation between individuals
is being assessed at the level of single nucleotide poly-
morphisms (SNP). Over a million SNPs have been detect-
ed in the normal population. The picture that is being
painted is that they are responsible for about 90% of
individual variation and that there is around 1-2 vari-
ants/gene. Such approaches augment classical genetic
strategies that are themselves becoming more efficient
and powerful. Advances in our ability to manipulate indi-
vidual genes is best seen in the numerous targeted
knock-in and knock-out strains of mice that have been
developed and that have given many new animal models
of human disease.
It is only natural that mRNA has emerged as
a prominent macromolecule in this quest for knowledge.
mRNA expression profiles are a reasonable reflection of
cell activity and function and can be read with a high
level of efficiency and reproducibility using cDNA or
oligonucleotide microarrays, which are becoming com-
mon currency in the search for cancer-related cellular
alterations. Quantitation of the “transcriptosome” is
improved by techniques such as serial analysis of gene
expression (SAGE). In addition, RNA is a dynamic ver-
satile macromolecule, attributable in part to the fact that
non-coding, as well as the coding, regions of the DNA
are transcribed and confer properties such as molecular
stability. RNA-based science is a promising approach in
therapeutics. mRNA is an accessible target for specific
inhibition of gene products, for example using anti-sense
agents or ribozymes, the RNA versions of enzymes that
digest specified sequences of mRNA, These approaches
are being tested in phase I trials, for example, to target
the transcript for the vascular endothelial growth factor
(VEGF) receptor.
It should not be forgotten that the current genocen-
tric view of cancer is just that, a current view. Bridging
genotype with phenotype is the major feat that
researchers and clinicians need to accomplish in this
post-genomic era. The proteome is still difficult to com-
prehensively interrogate. Protein analyses are less reli-
able and more restrictive than those at the genome or
mRNA level and the magnitude of the challenge is
greater. The proteome may be 100 fold larger than the
genome due to alternative splicing of mRNA and
post-transcriptional and post-translational processing but
progress is being made even at this level, in particular
using mass spectrometry techniques. In addition, tissue
arrays are now commonly used to examine expression of
multiple proteins by immunohistochemistry in patient
biopsy samples. These form a natural practical extension
of gene arrays that can be focused on expression of
defined prognostic molecular profiles and at the same
time confirm gene expression at the protein level, testing
up to 100 products on one slide. At the same time, tran-
scriptional silencing and post-transcriptional modifica-
tion of protein expression levels is becoming increasingly
recognized as important in carcinogenesis, prognosis, and
therapy.
A current impediment to progress is the lack of
methods for analyzing how gene products network in an
ontological sense to generate meaningful subcellular and
cellular systems that are capable of social molecular inter-
actions and intelligent responses to external signals. The
basis for this field of bioinformatics is embedded in cur-
rent literature on molecular circuitry of the cell and the
need to bridge genotype with phenotype in this
post-genomic era. It is difficult to use expression profiles
to identify nodal molecules within networks that dictate
and direct downstream events and that could serve as
critical targets for biological therapeutic intervention.
The tools for intervention are however becoming
increasingly available in the form of small molecule
inhibitors, monoclonal antibodies, gene therapeutics, or
elaborations of these approaches. An alternative
approach to identifying potentially critical molecular tar-
gets for cancer treatment is systematic searching of the
entire genome of a wide range of cancer types in the
hope of identifying common mutations. This approach
has already achieved some success with the identifica-
tion of BRAF mutations associated with 59% of
melanomas [1, 2]. The hope is that the definition of spe-
cific molecular targets for intervention will collude with
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high throughput drug production and testing systems that
are already well developed and are resulting in production
of a wide range of new biological therapeutics.
The new paradigm therefore presents a compelling
view of the future (Figure 1). The genetic profiles of the
individual patient and their cancer are typed and thera-
pies are chosen off-the-shelf that “fit” the profile for that
specific patient. In other words, they provide a molecular
readout that maximizes the therapeutic benefit. Following
initiation of treatment, molecular analyses will determine
the level of toxicity and response to therapy by employing
surrogate markers to assess benefit at early time points
rather than rely on tumor recurrence or tumor-free sur-
vival as endpoints. The importance of early assessment of
response cannot be underestimated. It allows patient
selection during treatment, the cost of clinical trials to
be minimized, and an increase in the number of com-
pounds that can be tested. Currently, the number of
promising compounds being produced exceeds the num-
ber of patients that might readily be entered into a trial
and the basis for a compound “making” it to Phase III
clinical trials is frequently of dubious scientific validity.
Prioritizing questions to be asked with the new
biotechnology
Given the potential impact of the emerging technologies,
this is a good time to prioritize the questions that might
be asked so that their implementation in cancer prog-
nostics, diagnostics, and therapy might be optimized.
In recent years it has become clear that therapies
induce molecular responses and that these may influence
therapeutic outcome. Predicting outcome might there-
fore be possible by determining the therapy-induced mol-
ecular profile in normal tissues and cancers in individual
patients. However, progress may be slow. For example,
preliminary data suggest 150-200 genes may be activated
rapidly following exposure to DNA damaging agents [3].
Evaluation of responses is further complicated because
different genes can be switched on at different times and
to differing extents in different tissues. Furthermore, late
responses, such as those to radiation therapy that gen-
erally limit the dose that is given, are likely to reflect dif-
ferences in genetic programs related to healing rather
than a direct response to radiation.
Greater value might be obtained by assessing varia-
tion between individuals and cancers prior to therapy,
using SNPs, microsatellite, gene methylation, and similar
analyses. It seems highly possible that radiation or
chemosensitive individuals will have polymorphisms in
specific genes. For example, polymorphisms in the
thymidylate synthase enhancer region can influence pro-
tein levels and survival of colorectal cancer patients
receiving 5-FU based therapy [4], as can polymorphisms
in glutathione S-transferase gene in patients receiving
5-FU/oxaliplatin chemotherapy [5]. Gene expression pro-
files prior to therapy might therefore identify individuals
and cancers that are intrinsically sensitive to certain ther-
apeutics. Such studies would also be important in estab-
lishing the baseline for studies on radiation-induced gene
expression.
The concept of genetically determined variation in
normal tissue response seems anathema to some radiation
oncologists, but animal and clinical data suggest that sen-
sitive individuals exist although their frequency and the
magnitude of their sensitivity are uncertain [6, 7].
Currently, it seems that radiosensitivity might be impact-
ed not so much by heterozygous expression of classical
genes such as those mutated in ataxia telangiectasia
(ATM) and other extreme radiosensitivity disease states,
but more by genes involved in DNA, cell, and tissue
repair. If this endeavor is successful, identification of
“radiosensitive” individuals will do away with the con-
cept of standard tolerance doses of radiation that are
currently applied to all patients, irrespective of genotype.
It is germane to ask whether predictive assays for
tumor radioresponsiveness will be of value and whether
these will relate most to molecular phenotype of the can-
cer, proliferation markers, radiation-induced gene expres-
sion pattern, hypoxic pattern, or all of the above. Some
clues can be obtained from the information that is begin-
ning to emerge from the use of genetic profiling of can-
cers.
A major current focus of gene microarray analysis
for cancer is molecular staging. The aim is to develop
prognosis classifiers to distinguish tumor subsets. If these
are of manageable size they can be validated for patient
outcome at the protein level using archival tissue arrays.
Most would agree that, at least for solid tumors, current
staging criteria lack predictive power and that apparently
homogenous cancers show marked variation in behavior
and response to therapy. In breast, lung, and lymphoid
malignancies in particular, sufficient evidence is already
available to suggest a revolution in cancer staging is com-
ing, even though the data are from studies involving tens
of samples rather than the hundreds that would be
desired [8].
The data that are generated by gene microarrays are
prodigious in quantity. For analysis, unsupervised hierar-
chical clustering algorithms are commonly used to cluster
genes in one dimension based on similarity in expression
levels and samples are clustered in the other dimension
based on their similarities. Filters are imposed to select
genes that vary maximally between patients. While these
filters make the data of a convenient size to be handled,
information that may be valuable can be discarded.
However, the power of the approach is already obvious.
In lung, Garber used microarrays to show that large
cell (LCC), small cell (SCLC), squamous cell (SCC), and
adenocarcinomas can be distinguished from each other
based on molecular profile with reproducibility that is
superior to conventional histological assessment [9]. As
might be expected, LCC had markers associated with
epithelial/mesenchymal cells, SCLC of neuroendothelial,
and SCC of well-differentiated cells. In addition, three
subgroups of adenocarcinomas were defined. Inte-
restingly, patients in these subgroups showed markedly
different disease-free survival. It was concluded that, in
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general, molecular classification can be achieved with
less than 100 genes and this meets the goal of identifying
a small subset of prognosis classifier genes for each tumor
type.
There is increasing suggestive evidence that in many
cases intrapatient variation, for example between prima-
ry tumor and metastatic deposit, may be considerably
less than variation between patients. This suggests that the
metastatic phenotype is expressed within the primary.
Indeed, van’t Veer et al. [10] have used expression pro-
filing of tumors from node negative women under 55 with
sporadic breast tumors less than 5cm to predict from the
profile of the primary tumor those patients who are like-
ly to fail at distant sites and could benefit from adjuvant
therapy. Sensitivity was 91% and specificity 73%.
Currently, only 20% of patients actually benefit from
adjuvant treatment, while 70-90% may be advised to have
it. Using molecular forecasting, it was predicted that only
20% would receive unnecessary treatment without an
increase in wrong assignments saving a large number of
patients the toxic and emotional damage associated with
administration of adjuvant chemotherapy.
There is a need to express caution concerning this
and similar studies. Normally the sample size is small;
typically less than 100 and the studies are retrospective in
nature. Those that use clinical outcome to guide the selec-
tion of a prognosis classifier cluster of genes may have an
intrinsic bias. Furthermore, most studies performed so
far can be considered to be using gene profiling only to
establish proof-of-concept. Treatment and clinical fac-
tors are not given much consideration. However, the
potential is obvious and it is worth asking what impact
molecular staging will have on radiation therapy and the
design of further molecular investigations involving radi-
ation therapy.
It is well recognized that plots of tumor control prob-
ability (TCP) with dose from clinical data show a flatter
dose response curve than would be expected from theo-
retical considerations. There are many possible reasons
for flat TCP curves [11]. Variation in tumor volume/num-
ber of clonogens between tumors contributes, but inter-
tumoral variation in intrinsic radiation sensitivity, prolif-
eration potential, and hypoxic status would have the same
end-result. It has long been recognized that the propor-
tion of cells surviving radiation in vitro varies roughly
with histological tumor type and this pattern is generally
consistent with clinical radiocurability. Variation in intrin-
sic cellular radiosensitivity has been considered to be evi-
dence that the way tumors perceive and respond to radi-
ation damage is important in determining outcome i.e. it
is not only the energy that is deposited that matters but
also the molecular wiring of the cell [12]. Furthermore,
the pathways involved can be altered by mutations in
oncogenes and tumor suppressor genes that often, but
not invariably, increase resistance to the cytotoxic effects
of radiation [13]. More accurate staging using molecular
criteria may therefore identify tumor subtypes prior to
therapy that vary in their intrinsic radiation response.
One result may be steeper TCP curves and better defini-
tion of dose response relationships. The extent of the
improvement in tumor control cannot be predicted, but it
important that the radiation community becomes involved
in correlating outcome from radiation therapy with mol-
ecular staging profiles.
The broader hope is that molecular profiling will be
able to redefine at the molecular level the impact of the
4 R’s of radiobiology that relate most closely to dose frac-
tionation in radiation therapy. Accurate molecular staging
would seem to be a prerequisite for these studies. For
example, intrinsic molecular markers of hypoxia, such as
CA-IX, HIF-1α, and VEGF, in some tumor sites may
correlate with disease-free survival better than with local
control following radiation therapy. In other words hypox-
ia, in particular chronic hypoxia, may reflect tumor pro-
gression and be of less radiobiological interest and relat-
ed more to cancer biology than has been suggested in
the past [14, 15]. If this is true, clearly, any analysis of
hypoxia-induced gene profiles would be more powerful if
the broader molecular subtype of the tumor was included
in the analysis. Similarly, molecular staging would pro-
vide a more powerful experimental framework for study
of the relationship between proliferation and cell cycle
markers, apoptotic markers, expression of repair enzymes,
and radiation response. There is optimism that this will be
possible. For example, a method for analysis of data
gleaned from microarrays that assigns a score to each of
6800 genes on the basis of change in expression relative to
a standard deviation in repeated measurements has iden-
tified 34 radiation-responsive genes in human lym-
phoblastoid cells [16]. Of these 34, 19 were involved in cell
cycle regulation, 13 in apoptosis, and 4 in nucleotide exci-
sion repair. Further clinical studies will be required to
develop a full picture of radioresponsiveness and this will
take considerable effort in collection of tumors, clinical
data, and automated analyses of a large number of spec-
imens, but are essential if radiation therapy is to be tai-
lored to the individual patient.
Targeted therapies
There is optimism that advances in molecular forecasting
will lead to identification of treatment options that are tai-
lored to individual patients. This requires that the mole-
cular aberrations associated with a tumor that distin-
guishes it from normal tissue are defined so as to allow
specific biological targeting. In theory, such approaches
should be highly tumor-specific and not associated with
the toxicity that limits the use of radiation and chemother-
apy. This begs the question as to whether biological tar-
geted therapies will eventually replace conventional ther-
apies.
Several potential problems with tumor-specific bio-
logical therapies have been noted. For example, while
cancer is a clonal and genetic disease, it is associated with
a constellation of changes that may occur in unique or
mutation-specified temporal sequences. These multiple
genetic changes give rise to heterogeneity, even within
one tumor, as can epigenetic influences, such as gene
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silencing through exon/promoter methylation or post-
translational modifications in gene expression.
Targeting any one cancer-related alteration may
therefore be of limited value, although some proof of
principle that genetic alterations can be targeted has been
obtained with the use of herceptin for the EGFR member
Her2neu in breast cancer and Gleevac for Bcr-ABL in
CML. In both cases, prescreening has been critical for
establishing efficacy and in the case of Gleevec post-treat-
ment monitoring of crk phosphorylation and loss of the
Philadelphia chromosome has been useful in assessing
response. The message is that molecular analyses will be
important if other similar strategies are to show efficacy.
The argument can be made that individual tumors
are “addicted” to a particular pathway or that specific
mutated molecules act as “nodal” directors of multiple
pathways and that, in spite of multiple genetic changes,
targeting one molecule may be sufficient to achieve
a therapeutic benefit. While this is possibly true, it is not
easy to define the critical pathway or molecule and intra-
tumoral heterogeneity in their expression suggests that
escape variants are likely to occur that will be responsible
for failure of even effectively targeted agents.
It would be useful if the impact of specific oncogene
or tumor suppressor gene mutations could be readily
identified and downstream events identified that might
indicate alternative targets and the importance of the
pathway for tumor survival. Sorlie et al [17] were able to
identify ER-ve and +ve groups of breast carcinomas that
differed by about 150 genes. Interestingly, only 15% could
be called ER discriminators and only about half of these
were directly estrogen responsive. In other words, most of
the genes distinguishing these subsets are secondarily
responsive or related to tumor origin or progression.
Alternatively, the gene microarray approach may not be
sufficiently discriminatory to reliably identify distinct
pathways. Certainly, the analysis, which typically includes
an increase or decrease in mRNA expression levels of
2 or 2.5 fold is arbitrary and may bear little relationship to
protein expression levels. They are also heavily influ-
enced by gene copy number involving large segments of
the genome [18]. This highlights the potential problems of
identifying meaningful targets associated with molecular
survival pathways. On the other hand, Sorlie did identify
an ErbB2 rich group of ER-ve breast carcinomas that
had a distinct phenotype and outcome [19]. These could
be distinguished from basal cell and 3 luminal mammary
carcinoma subgroups. p53 mutation was associated with
several subsets. Using patient survival in supervised learn-
ing programs to guide the clustering showed that 90%
of those that correlated best with survival also self-orga-
nized into the main tumor molecular subtypes. The con-
clusions from this study were that gene expression profil-
ing can define subtypes within the biological diversity of
tumors even in the presence of oncogenes and tumor
suppressor gene mutations, and that these mutations can
be associated with a distinct molecular profile that relates
to patient survival.
It is worth considering the lessons learnt so far with
biologically targeted therapies. Perhaps the most popular
current target for preclinical and clinical investigation is
the EGFR-related system and its downstream pathways.
EGFR is overexpressed in many cancers and targeting
EGFR blocks tumor cell proliferation and encourages
cell death [19]. Monoclonal antibodies, small molecule
inhibitors, and gene therapy approaches have all been
developed. Indeed, perhaps the great diversity of agents
that are in preclinical and clinical development [19] serves
as an indication of how inept we are at judging potential
efficacy. In preclinical in vivo models, the monoclonal
antibody C225 has been shown to slow tumor growth
[20], as have many small molecular inhibitors, but tumor
regression is rare. There are many small molecule
inhibitors in preclinical and clinical development, but
those in the most advanced stages of development, like
Iressa, show limited efficacy and dose-limiting toxicity
even when combined with chemotherapy [21].
In short, in spite of the enormous enthusiasm for
biological targeting, the available evidence suggests that
there are problems to be overcome. In addition to het-
erogeneity of expression and escape variants, specificity
can be an issue. The small molecule inhibitors of EGFR
have side effects related to normal tissue expression of
EGFR, perhaps more than with monoclonal antibodies
because of their more homogeneous distribution [21].
Also, many inhibitors are not truly tumor-specific. Even
Gleevac was designed to inhibit a different target than
Bcr-Abl, namely platelet-derived growth factor, and is
not without normal tissue toxicity. However, arguably the
most serious drawback is that biologically targeted agents
tend to be cytostatic rather than cytotoxic, or at least are
not toxic for all tumor cells. To cure cancer you need to
kill all the cancer cells! Partial responses are not of great
therapeutic value. It is therefore not surprising that, in
most cases, biologically targeted agents work far better
when combined with classic cytotoxic agents like radiation
or chemotherapy.
Another problem is that, while small molecule
inhibitors and monoclonal antibodies may be of use in
targeting oncogene-related mutations and overexpressed
or aberrantly expressed molecules, they are of little value
for tumor suppressor gene (loss of function) mutations.
Most strategies aimed at these mutations rely on gene
therapy, which has considerable limitations. Gene thera-
py is a lovely concept, but inefficiency of the vectors is
a major issue. The best transduction efficiencies we are
able to achieve, even in preclinical tumor models were
about 50% [22]. This dictates that a bystander effect is
needed to affect the other cells in the tumor that could
not be transduced. Current approaches, even using repli-
cating vectors or tumor-specific vectors, are therefore
limited. Further, tumor suppressor gene replacement is
generally cytostatic not cytotoxic and, while for example
p53 gene replacement in preclinical models slows tumor
growth in vitro and in vivo, examples of cures are rare
[22]. In general, tumor suppressor gene replacement
19
seems to work far better if combined with a powerful
cytotoxic agent like radiation therapy.
Conclusions
The above discussion suggests that molecular forecast-
ing of the response of individual patients and their cancer
to therapy is going to be greatly improved by the new
biotechnologies and that this should lead to the identifi-
cation of novel targets and strategies with a high thera-
peutic index. The tools for specific biological targeting
of cancer are also becoming readily available and biolog-
ically targeted therapies are going to become common
currency in cancer therapy. However, they are unlikely to
be effective as sole therapies. They will still need to be
combined with powerful cytotoxic agents, like radiation.
In order for radiation oncologists to derive benefit from
the biological revolution on behalf of their patients, the
concept that molecular signaling pathways may be acti-
vated in cancer that distinguish cancer from normal tis-
sues and determine cellular radiation responses needs to
be embraced by the radiation community and trials devel-
oped to investigate these new combined therapies. The
baseline for these therapeutic investigations, as well as
prognostic studies in radiation therapy, should be that
cancers are molecularly staged since this may more pre-
cisely profile the disease. The influence of hypoxia, cell
cycle, proliferation, and repair should be evaluated with-
in this context. Radiation oncologists should embrace
this formula and use the new biotechnologies, with asso-
ciated critically important clinical assessment and sample
collection, as a basis for evaluating combined therapy
approaches using novel biologically targeted drugs and
gene therapy approaches along with radiation therapy.
William H. McBride D.Sc.
Roy E. Coats Laboratories, 
Department of Radiation Oncology
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